Advancements in Acute Myeloid Leukemia Treatment

Dr. Courtney DiNardo of the MD Anderson Cancer Center discusses the difficult to treat acute myeloid leukemia (AML).  She shares findings from the phase 3 VIALE-A study published in the “New England Journal of Medicine” (NEJM Aug 2020) that showed that venetoclax combination with azacitidine helped newly-diagnosed AML patients ineligible for intensive chemo, live longer without progression of their disease than with azacitidine alone and how this combination is potentially a “practice changing” advance in AML treatment.

Dr. Courtney DiNardo is a clinical researcher at MD Anderson Cancer Center with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She is the lead investigator of the VIALE-A study, evaluating venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.